

A review of biomarkers relating to cancer-related symptom burden and quality of life

Leigha Rowbottom¹, MD(C), Stephanie Chan¹, BSc(C), Bo Angela Wan¹, MD(C), Pearl Zaki¹, BSc(C), Matthew Choi¹, BSc, Anthony Furfari¹, MD(C), Rachel McDonald¹, MD(C), Carlo DeAngelis¹, PharmD, Azar Azad^{2,3,4}, PhD, Ronald Chow¹, BMSc(C), Henry Lam¹, MLS, Edward Chow¹, MBBS and George S Charames^{3,4,5,*}, PhD



¹Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto
²Mount Sinai Services Inc., Toronto
³Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto
⁴Laboratory Medicine and Pathobiology, University of Toronto, Toronto
⁵Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto



Introduction

- Cancer and associated treatments often have significant impact on patients and can manifest in a variety of symptoms leading to negative outcomes on health-related quality of life (HRQOL).
- Certain symptoms may occur in conjunction, also referred to as a symptom cluster, which can lead to aggregate burden on the patient.
- Symptom clusters may occur together as there may be one true underlying etiology, which if identified could provide therapeutic targets for enhanced symptom management.
- Biomarkers may provide clues to physicians as to what the cause of a symptom or symptom cluster is, as well as to help identify symptoms in non-communicative patients.

Objective

To summarize the available literature regarding biological and genetic biomarkers related to cancer-related symptoms and quality of life (QOL) in cancer patients.

Methods

A systematic literature review was conducted using Medline and Embase (1947 to 2016 Week 16). A combination of keywords was utilized including “inflammation”, “cancer pain”, “neoplasm”, “biological marker”, “allele”, and “genomics”. Articles were limited to studies conducted in humans and reported in English. The literature search resulted in a total of 5,480 articles that were screened by title then abstract.

Selected references

- Bower JE, Ganz PA, Tao ML, Hu W, Belin TR, Sepah S, et al. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. *Clin Cancer Res* 2009;15(17):5534-40.
- Perry EB, Mulay SB, Kamath J, Dowsett RJ, Neuwirth J, Grady J, et al. Factors influencing fatigue in breast cancer patients undergoing breast irradiation. *J Clin Oncol* 2015;33(Suppl):e20690.
- Pertl MM, Hevey D, Boyle NT, Hughes MM, Collier S, O'Dwyer AM, et al. C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy. *Brain Behav Immun* 2013;34:108-19.
- Reinertsen KV, Grenaker Alnaes GI, Landmark-Høyvik H, Loge JH, Wist E, Kristensen VN, et al. Fatigued breast cancer survivors and gene polymorphisms in the inflammatory pathway. *Brain Behav Immun* 2011;25(7):1376-83.
- Bower JE, Ganz PA, Aziz N, Fahey JL, Cole SW. T-cell homeostasis in breast cancer survivors with persistent fatigue. *J Natl Cancer Inst* 2003;95(15):1165-8.
- Collado-Hidalgo A, Bower JE, Ganz PA, Cole SW, Irwin MR. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. *Clin Cancer Res* 2006;12(9):2759-66.
- Courtier N, Gambling T, Enright S, Barrett-Lee P, Abraham J, Mason MD. Psychological and immunological characteristics of fatigued women undergoing radiotherapy for early-stage breast cancer. *Support Care Cancer* 2013;21(1):173-81.
- Mitsunaga S, Ikeda M, Nakachi K, Kojima Y, Oono I, Shimizu S, et al. Serum interleukin-6 level is associated with hepatic inflammatory response and fatigue in advanced pancreatic cancer. *Ann Oncol* 2010;21:ix19.
- Kurz K, Fiegl M, Holzner B, Giesinger J, Pircher M, Weiss G, et al. Fatigue in patients with lung cancer is related with accelerated tryptophan breakdown. *PLoS One* 2012;7(5):e36956.
- Paddison JS, Temel JS, Frichione GL, Pirl WF. Using the differential from complete blood counts as a biomarker of fatigue in advanced non-small-cell lung cancer: an exploratory analysis. *Palliat Support Care* 2009;7(2):213-7.
- Light KC, Agarwal N, Iacob E, White AT, Kinney AY, VanHaitsma TA, et al. Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome. *Psychoneuroendocrinology* 2013;38(12):2983-95.
- Penafuerte CA, Gagnon B, Sirois J, Murphy J, MacDonald N, Tremblay ML. Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia. *Br J Cancer* 2016;114(6):680-7.

Results

A total of 41 articles were identified for inclusion

Fatigue

- ❖ Increased levels of pro-inflammatory serum cytokines and their receptors were associated with fatigue in patients undergoing radiotherapy.
- ❖ Multiple studies found elevated CRP being correlated with fatigue
- ❖ Several studies showed that patients experiencing severe fatigue were found to have elevated levels of lymphocytes such as T-lymphocytes, neutrophils, and monocytes
- ❖ No genetic variations were identified

Cancer Cachexia

- ❖ Cachectic patients across 7 cancer types were all found to have elevated IL-6, IL-8 and absolute neutrophil levels. Cachectic and Pre-cachectic were also found to have elevated angiotensin II, TGFB1, and also increased mRNA expression of neutrophil-derived proteases
- ❖ Other studies showed that cachectic patients also had increased ubiquitin mRNA, with decreased overall testosterone levels
- ❖ Similar to other markers of QoL, elevated levels of pro-inflammatory cytokines (CRP, TNF-R1, and TNF-a) is associated with poorer outcomes such as cachexia.

Depression, Anxiety, and Neurocognitive Complaints

- ❖ Val66Met variant of BDNF, increased CRP were found to be significant predictors of depressive symptoms in early-stage breast cancer patients
- ❖ Another study showed that increased IL-10, and decreased IL-4 were heavily associated with increased anxiety
- ❖ Memory performance was also found to be related to soluble levels of TNF-RII

Symptom Burden and Quality of Life

- ❖ IL6 was found to be correlated with pain and reduced QoL in breast cancer survivors
- ❖ Others reported that IL6 was linked to disturbed sleep, distress, and mood interference patients suffering from colorectal cancer and various other cancers
- ❖ CRP levels were evaluated in 3 different studies, with each reported that elevated CRP being linked to poorer HRQoL.
- ❖ Additional studies showed that higher baseline levels of CRP, VEGF, and neutrophil:lymphocyte ratio was associated with anorexia, fatigue and poorer QoL
- ❖ Variations of IL1B, JAK2, IL1R2, NFKB2, TNFR1 were all found to have provided differential experiences in QOL from cancer patients
- ❖ 174GG genotype for the IL6 gene in non-Hispanic white patients was found to be a

Discussion

- ❖ Appropriate evaluation of patient risk for pain, fatigue, nausea, and depression, not only helps with outcomes but also the guidance provided by healthcare providers to family members for appropriate care
- ❖ High levels of inflammatory protein biomarkers have been linked to increases in immunological biomarkers and poor cancer symptoms.
- ❖ Animal models studying the “cytokine-immunologic model” for cancer symptoms have shown that administering pro-inflammatory agents generates sickness that mirrors cancer symptoms, and could be a potential treatment target
- ❖ Genetic analysis for genetic variants have produced mixed results but have potential

Conclusion

- ❖ this study highlights a complicated network of neuroendocrine-immuno-chemical-cognitive network that seems to modulate both cognitive and physical symptoms in cancer patients.
- ❖ Future research should look to delineate this relationship to better understand how these different systems integrate and connect with one another.

Acknowledgement: We thank the generous support of the Joey and Mary Furfari Cancer Research Fund.